Approval · Notice of Compliance 13692 · 2012
APO-RIZATRIPTAN: Notice of Compliance 13692
Issued September 27, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13692
- Date
- September 27, 2012
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- 5-HT1 Receptor Agonist; Migraine Therapy
- Canadian reference product
- MAXALT
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-RIZATRIPTAN | 02393468 | Marketed |
| APO-RIZATRIPTAN | 02393476 | Marketed |
Medicinal ingredients
- RIZATRIPTAN BENZOATE 5 MG per TAB
- RIZATRIPTAN BENZOATE 10 MG per TAB